HIV and HCV Medications in End-Stage Renal Disease

Keiko I. Greenberg, Mark A. Perazella, Mohamed G. Atta

Research output: Contribution to journalArticlepeer-review

Abstract

Human immunodeficiency virus (HIV) infection and hepatitis C virus (HCV) infection affect populations worldwide. With the availability of over 35 Food and Drug Administration approved medications for treatment of HIV, the morbidity and mortality associated with HIV has greatly improved. On the other hand, treatment options for HCV have been limited until very recently. While the use of protease inhibitors (such as boceprevir and telaprevir) has become standard of care for treatment of hepatitis C in the general population, data for individuals with impaired kidney function, particularly those on dialysis, are extremely limited. Use of medications in dialysis patients can be challenging given the dose adjustments that must be made for renally cleared molecules, and potentially increased impact of adverse effects such as anemia. Recommendations for dosing of marketed therapies for HIV and HCV are reviewed.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalSeminars in dialysis
Volume28
Issue number4
DOIs
StatePublished - Jul 1 2015

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'HIV and HCV Medications in End-Stage Renal Disease'. Together they form a unique fingerprint.

Cite this